-

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the following upcoming conferences, which are being conducted in-person:

  • Guggenheim 2nd Annual Healthcare Innovation Conference: Fireside chat on Monday, November 10, 2025, at 4:30pm ET in Boston, Massachusetts
  • 8th Annual Evercore Healthcare Conference: Fireside Chat on Tuesday, December 2, 2025, at 8:20am ET in Coral Gables, Florida
  • Citi's 2025 Global Healthcare Conference: Fireside Chat on Wednesday, December 3, 2025, at 4:00pm ET in Miami, Florida

A live webcast of each fireside chat can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

Contacts

Media
Amylyx Media Team
+1 (857) 320-6191
amylyxmediateam@amylyx.com

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Release Summary
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
Release Versions
$Cashtags

Contacts

Media
Amylyx Media Team
+1 (857) 320-6191
amylyxmediateam@amylyx.com

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com

Social Media Profiles
More News From Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial...

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the third quarter ended September 30, 2025. “Entering the final months of 2025, we are focused on execution as we head toward a transformative year in 2026, with topline data expected from the pivotal Phase 3 LUCIDITY trial,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “We continue to advance our lead asset avexitide, an investiga...

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025...
Back to Newsroom